Omnicell, Inc. (NASDAQ:OMCL):
CompleteRx Partners with Omnicell to Support the Commonwealth of Massachusetts State Office of Pharmacy Services.
The company is now down by -0.29 percent from yesterday’s close.
Omnicell, Inc. (Omnicell), launched on April 14, 2000, is a provider of automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. The Company operates through two segments: Automation and Analytics, and Medication Adherence..
It is trading at $42.45 which is slightly above the 50 day moving average which is $41.24 and marginally over the 200 day moving average of $37.80. The 50 day moving average was up $1.21 or +2.94% and the 200 day average moved up $4.65.
As of the last earnings report the EPS was $-0.27 and is estimated to be $1.28 for the current year with 37,163,000 shares now outstanding. Next quarter’s EPS is forecasted to be $0.45 and the next full year EPS is anticipated to be $2.05.
Investors are more bullish on shares of the company recently if you take a look at the motion in short interest. The firm realized a fall in short interest of -9.48% between May 15, 2017 and April 28, 2017. Short interest fell from 4,272,706 to 3,867,525 over that timeframe. Days to cover decreased from 14.7 to 11.4 and the short interest percentage is 0.10% as of April 28.
Wall Street investment firms have provided guidance on Omnicell, Inc.. On September 8 the stock rating was downgraded to “Neutral” from “” in an announcement from Sidoti & Co.. On July 29 FBR Capital kept the stock rating at “Outperform” but raised the price target to $41.00 from $33.00.
Equity analyst Benchmark initiated coverage on the stock setting a rating of “Buy” and setting a price target of $33.00. October 30 investment analysts at Piper Jaffray held the stock rating at “Overweight” but moved down the price target from $43.00 to $42.00.
Oppenheimer starting coverage on the stock with an initial rating of “Outperform” and a price target of $44.00. October 31 investment analysts at FBR Capital left the stock rating at “Outperform” and raised the price target to $33.00 from $31.00.